Xcell Therapeutics Risks Watchlist Designation as Market Cap Stays Below KRW 20 Billion

PUBT · 1d ago
Xcell Therapeutics Risks Watchlist Designation as Market Cap Stays Below KRW 20 Billion
  • Xcell Therapeutics faces potential designation as a management stock under Kosdaq listing rules.
  • The rules require designation when common-share market capitalization remains below KRW 20 billion for 30 consecutive trading days.
  • Its market capitalization had remained below that threshold for 25 consecutive trading days as of Nov. 20, 2026.
  • Designation could follow if the shortfall persists for five more trading days starting Nov. 23, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xcell Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261120900866), on November 20, 2026, and is solely responsible for the information contained therein.